Effect of diuretics on cardiac arrhythmias and left ventricular hypertrophy in hypertension

V Papademetriou1

  • 1Department of Veterans Affairs, Medical Center, Washington, DC 20422.

Cardiology
|January 1, 1994
PubMed

Insights

Diuretic therapy does not increase ventricular arrhythmias in hypertensive patients. These drugs effectively reduce left ventricular hypertrophy (LVH), a key risk factor for cardiovascular events.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ventricular arrhythmias are a significant risk in hypertension.
  • Previous concerns about diuretics causing arrhythmias were based on heart failure patients, not hypertensive individuals.
  • The link between hypokalemia and arrhythmias in hypertensive patients on diuretics is inconclusive.

Purpose of the Study:

  • To evaluate the effect of diuretic therapy on ventricular arrhythmias in hypertensive patients.
  • To assess the impact of diuretics on left ventricular hypertrophy (LVH) in hypertension.
  • To determine if correcting hypokalemia affects arrhythmia incidence.

Main Methods:

  • Prospective studies were conducted in hypertensive patients.
  • Arrhythmia incidence was monitored at rest, during, and after exercise.
  • Left ventricular hypertrophy (LVH) was assessed in relation to diuretic use and antihypertensive therapy.

Main Results:

  • Diuretic therapy showed no effect on the incidence of serious ventricular arrhythmias in hypertensive patients, with or without LVH.
  • Correction of diuretic-induced hypokalemia did not alter the incidence of ventricular arrhythmias.
  • Diuretics were effective in reducing LVH, with some studies showing greater reduction compared to other antihypertensives.

Conclusions:

  • Diuretics are safe regarding ventricular arrhythmias in hypertensive patients.
  • Diuretics are effective agents for reducing LVH, a critical target in hypertension management.
  • Diuretic therapy should be considered for its benefits in managing hypertension and associated LVH.

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...